Literature DB >> 22418977

Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction.

Naïke Bige1, Nasim Shweke, Safa Benhassine, Chantal Jouanneau, Sophie Vandermeersch, Jean-Claude Dussaule, Christos Chatziantoniou, Pierre Ronco, Jean-Jacques Boffa.   

Abstract

Thrombospondin-1 (TSP-1) is an endogenous activator of transforming growth factor-β (TGF-β), and an anti-angiogenic factor, which may prevent kidney repair. Here we investigated whether TSP-1 is involved in the development of chronic kidney disease using rats with unilateral ureteral obstruction, a well-known model to study renal fibrosis. Obstruction of 10 days duration induced inflammation, tubular cell atrophy, dilation, apoptosis, and proliferation, leading to interstitial fibrosis. TSP-1 expression was increased in parallel to that of collagen III and TGF-β. Relief of the obstruction at day 10 produced a gradual improvement in renal structure and function, the reappearance of peritubular capillaries, and restoration of renal VEGF content over a 7- to 15-day post-relief period. TSP-1 expression decreased in parallel with that of TGF-β1 and collagen III. Mice in which the TSP-1 gene was knocked out displayed less inflammation and had better preservation of renal tissue and the peritubular capillary network compared to wild-type mice. Additional studies showed that the inflammatory effect of TSP-1 was mediated, at least in part, by monocyte chemoattractant protein-1 and activation of the Th17 pathway. Thus, TSP-1 is an important profibrotic and inflammatory mediator of renal disease. Blockade of its action may be a treatment against the development of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418977     DOI: 10.1038/ki.2012.21

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  36 in total

1.  Dendritic cell-derived thrombospondin-1 is critical for the generation of the ocular surface Th17 response to desiccating stress.

Authors:  Niral B Gandhi; Zhitao Su; Xiaobo Zhang; Eugene A Volpe; Flavia S A Pelegrino; Salman A Rahman; De-Quan Li; Stephen C Pflugfelder; Cintia S de Paiva
Journal:  J Leukoc Biol       Date:  2013-08-27       Impact factor: 4.962

Review 2.  Discoidin domain receptor-1 and periostin: new players in chronic kidney disease.

Authors:  Carlo Alfieri; Panagiotis Kavvadas; Paola Simonini; Masami Ikehata; Jean Claude Dussaule; Christos E Chadjichristos; Maria Pia Rastaldi; Piergiorgio Messa; Christos Chatziantoniou
Journal:  Nephrol Dial Transplant       Date:  2015-03-31       Impact factor: 5.992

Review 3.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

4.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

5.  Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure.

Authors:  Michael Zeisberg; Björn Tampe; Valerie LeBleu; Desiree Tampe; Elisabeth M Zeisberg; Raghu Kalluri
Journal:  Am J Pathol       Date:  2014-08-10       Impact factor: 4.307

Review 6.  Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

Authors:  Joanne E Murphy-Ullrich; Mark J Suto
Journal:  Matrix Biol       Date:  2017-12-27       Impact factor: 11.583

7.  The Thrombospondin1-TGF-β Pathway and Glaucoma.

Authors:  Joanne E Murphy-Ullrich; J Crawford Downs
Journal:  J Ocul Pharmacol Ther       Date:  2015-05-29       Impact factor: 2.671

8.  Myeloid-specific deletion of thrombospondin 1 protects against inflammation and insulin resistance in long-term diet-induced obese male mice.

Authors:  Hasiyet Memetimin; Dong Li; Kaiyuan Tan; Changcheng Zhou; Ying Liang; Yadi Wu; Shuxia Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-23       Impact factor: 4.310

Review 9.  Role of thrombospondin 1 in liver diseases.

Authors:  Yanzhang Li; Courtney P Turpin; Shuxia Wang
Journal:  Hepatol Res       Date:  2016-08-30       Impact factor: 4.288

Review 10.  Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease.

Authors:  Yujiro Kida; Bie Nga Tchao; Ikuyo Yamaguchi
Journal:  Pediatr Nephrol       Date:  2013-03-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.